Novacyt Clamart (NVYTF): Launch of CE-IVD Marked novel coronaviru...

Launch of CE-IVD Marked novel coronavirus test

TB · 2020-02-24T11:43:37.6600000Z

Launch of CE-IVD Marked novel coronavirus test https://novacyt.com/2020/02/17/launch-of-ce-ivd-marked-novel-coronavirus-test/

Play Episode

6min

Proactive - Interviews for investors

Solvonis Therapeutics engages PharmaVentures to support key AUD assets

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

Proactive - Interviews for investors

North Bay Resources announces first gold concentrate sale from Fran Gold Project

North Bay Resources CEO Jared Lazerson joined Steve Darling from Proactive to share news of the company’s first successful gold concentrate sale from a test shipment processed at the Bishop Gold Mill, using ore from the Fran Gold Project. Lazerson confirmed that final acceptance and settlement have been completed, with all refinery requirements met, and assay comparisons for gold, silver, and moisture content agreed upon. The test concentrate represents approximately 10 tons of gross ore, processed through the gravity-only circuit. Lazerson noted this marks an important milestone in the early phase of operations. The flotation circuit, which is expected to significantly enhance recovery rates, is set to come online this month. The company currently has another test shipment in process and has completed a third concentrate shipment, further validating operational momentum. The most recent sale netted approximately $400 per ton, based solely on gravity recovery. However, with further optimization and the integration of the flotation circuit, recoveries are projected to double, potentially reaching over 90% total recovery. This would raise the value per ton to around $800, significantly improving project economics. North Bay Resources currently has 75 tons of ore stockpiled at the Bishop Gold Mill, which will be processed as part of continued optimization and ramp-up. Additionally, there are approximately 5,000 tons of ore stockpiled at the project site, positioning the company for a steady flow of future shipments as operations scale. The CEO also discussed the reinterpretation of 15 years of historical drilling data—104 holes covering 18,000 metres—which has revealed the potential for a bulk tonnage deposit. This reinterpretation aligns with nearby major low-grade, high-volume gold projects like Mount Milligan and Blackwater. #proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources #MiningNews #CaliforniaGold #JaredLazerson #G

Proactive - Interviews for investors

Buru Energy secures strategic deal for LNG development

Buru Energy Ltd CEO Thomas Nador talked with Proactive about the company’s newly announced strategic development agreement with Clean Energy Fuels Australia Pty Ltd (CEFA) to co-develop the Rafael Gas Project. Nador explained that CEFA brings strong midstream and downstream capabilities, backed by I Squared Capital, which manages around $40 billion in assets. "They bring the right credentials, to look after the downstream and midstream elements of the project," he said. Buru, meanwhile, will focus on the upstream side of the Rafael development. The deal is described as a “watershed moment” for the company, as it provides a clear pathway toward developing a long-term gas and condensate business in northwest Western Australia—an area currently dependent on imported energy. Under the agreement, CEFA will fund, build, and operate a small-scale LNG facility on-site, with Buru paying a processing fee over the life of the project. This significantly reduces Buru’s capital exposure to only the upstream infrastructure—namely, two wells, one of which is already in place. A final investment decision is expected in late 2025 or early 2026, with first cash flows anticipated in the second half of 2027. According to Nador, the projected annual free cash flow from the Rafael development is expected to surpass the company’s current market capitalization. For more insights like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future updates. #BuruEnergy #RafaelGasProject #LNGDevelopment #AustralianEnergy #CleanEnergy #GasExploration #CEFA #ThomasNador #ProactiveInvestors #ASXEnergy #NaturalGas #EnergyInfrastructure #I2Capital #UpstreamEnergy #MidstreamDevelopment

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Followers	147
Posts	12051
Boards Moderated	1
Alias Born	07/06/2007

Volume:	-
Day Range:
Bid:	0.0001
Ask:	800.61
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

NVYTF Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free